Bayer Aktiengesellschaft in 2 stories

The narratives BAYN.DE currently appears in, with its side and exposure in each.

0 stories

No bull-side stories for BAYN.DE yet.

2 stories

America Imports the World's Drug Prices
BAYN.DE in “America Imports the World's Drug Prices”
StableExposure: not rated yet
US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Bayer's growth drugs, including Nubeqa and Kerendia, face lower lifetime revenue potential if US reimbursement is benchmarked against discounted overseas prices.
The Patent Cliff Sparks a Biotech Land Grab
BAYN.DE in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yet
Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Patent erosion in major pharmaceutical franchises collides with balance-sheet and litigation constraints, limiting Bayer's ability to compete freely for scarce replacement assets.

2 stories

America Imports the World's Drug Prices
BAYN.DE in “America Imports the World's Drug Prices”
StableExposure: not rated yet
US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Bayer's growth drugs, including Nubeqa and Kerendia, face lower lifetime revenue potential if US reimbursement is benchmarked against discounted overseas prices.
The Patent Cliff Sparks a Biotech Land Grab
BAYN.DE in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yet
Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Patent erosion in major pharmaceutical franchises collides with balance-sheet and litigation constraints, limiting Bayer's ability to compete freely for scarce replacement assets.